Head-to-head evidence
ANX007 vs Vonaprument
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: Complement C1q · full Age-Related Macular Degeneration pipeline
ANX007
Developed by Annexon, Inc.
NCT04656561 · Phase 2 · completed
The trial used randomization, quadruple masking, and sham-controlled parallel groups with 270 participants, which is a strong study design. However, the registry has no posted primary-endpoint results, and the primary measure—growth of the atrophy lesion assessed by fundus autofluorescence—is an imaging-based surrogate rather than a direct visual-function outcome.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: October 2026 · NCT06510816 (registry estimate)
Vonaprument
Developed by Annexon, Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2026 · NCT06510816 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ANX007's landscape · Vonaprument's landscape